EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 16, 2020

Primary Completion Date

December 19, 2020

Study Completion Date

December 19, 2020

Conditions

Solid Tumor, Adult

Interventions

DRUG

INVAC-1 given in the previous phase 1 NCT02301754. No new injection is required in this study.

blood sampling will be drawn once in order to analyse long term memory immune response to INVAC-1 vaccine

Trial Locations (1)

Saint Louis Hospital, Paris